Drug intelligence / Profile preview

DermaBetic

Development stage: Unknown
Lead developer: Blaine Pharmaceuticals
Modality: Small Molecules
Administration: Topical

Overview

DermaBetic is a topical dermatologic and podiatric skin care cream developed by Blaine Labs (also known as Blaine Company). It is specifically formulated for the management of xerosis (mild-to-severe dry skin) and is frequently utilized as part of a comprehensive diabetic foot care regimen. The product's active profile includes urea, which serves as a humectant and keratolytic to enhance skin hydration and exfoliation; colloidal oatmeal, which provides soothing and anti-inflammatory benefits; and eggshell membrane, which is intended to support collagen production and improve skin elasticity. DermaBetic is a physician-dispensed product designed for daily use to maintain skin integrity and monitor foot health in diabetic populations.

Brand names: DermaBetic
Other names: DermaBetic Skin Cream

Beyond the preview

Go deeper on DermaBetic.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DermaBetic.

Explore the full profile